JP2019518427A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019518427A5 JP2019518427A5 JP2018554334A JP2018554334A JP2019518427A5 JP 2019518427 A5 JP2019518427 A5 JP 2019518427A5 JP 2018554334 A JP2018554334 A JP 2018554334A JP 2018554334 A JP2018554334 A JP 2018554334A JP 2019518427 A5 JP2019518427 A5 JP 2019518427A5
- Authority
- JP
- Japan
- Prior art keywords
- itr
- seq
- raav
- rbg
- eye
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022046261A JP7111924B2 (ja) | 2016-04-15 | 2022-03-23 | 滲出型加齢性黄斑変性の治療のための組成物 |
| JP2022116098A JP7492556B2 (ja) | 2016-04-15 | 2022-07-21 | 滲出型加齢性黄斑変性の治療のための組成物 |
| JP2024080598A JP2024105617A (ja) | 2016-04-15 | 2024-05-17 | 滲出型加齢性黄斑変性の治療のための組成物 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662323184P | 2016-04-15 | 2016-04-15 | |
| US62/323,184 | 2016-04-15 | ||
| US201662331100P | 2016-05-03 | 2016-05-03 | |
| US62/331,100 | 2016-05-03 | ||
| US201762442946P | 2017-01-05 | 2017-01-05 | |
| US62/442,946 | 2017-01-05 | ||
| US201762460515P | 2017-02-17 | 2017-02-17 | |
| US62/460,515 | 2017-02-17 | ||
| US201762466721P | 2017-03-03 | 2017-03-03 | |
| US62/466,721 | 2017-03-03 | ||
| PCT/US2017/027529 WO2017180936A1 (en) | 2016-04-15 | 2017-04-14 | Compositions for treatment of wet age-related macular degeneration |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022046261A Division JP7111924B2 (ja) | 2016-04-15 | 2022-03-23 | 滲出型加齢性黄斑変性の治療のための組成物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019518427A JP2019518427A (ja) | 2019-07-04 |
| JP2019518427A5 true JP2019518427A5 (enExample) | 2020-05-28 |
| JP7046828B2 JP7046828B2 (ja) | 2022-04-04 |
Family
ID=59253994
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018554334A Active JP7046828B2 (ja) | 2016-04-15 | 2017-04-14 | 滲出型加齢性黄斑変性の治療のための組成物 |
| JP2022046261A Active JP7111924B2 (ja) | 2016-04-15 | 2022-03-23 | 滲出型加齢性黄斑変性の治療のための組成物 |
| JP2022116098A Active JP7492556B2 (ja) | 2016-04-15 | 2022-07-21 | 滲出型加齢性黄斑変性の治療のための組成物 |
| JP2024080598A Pending JP2024105617A (ja) | 2016-04-15 | 2024-05-17 | 滲出型加齢性黄斑変性の治療のための組成物 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022046261A Active JP7111924B2 (ja) | 2016-04-15 | 2022-03-23 | 滲出型加齢性黄斑変性の治療のための組成物 |
| JP2022116098A Active JP7492556B2 (ja) | 2016-04-15 | 2022-07-21 | 滲出型加齢性黄斑変性の治療のための組成物 |
| JP2024080598A Pending JP2024105617A (ja) | 2016-04-15 | 2024-05-17 | 滲出型加齢性黄斑変性の治療のための組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (3) | US11197937B2 (enExample) |
| EP (1) | EP3452103A1 (enExample) |
| JP (4) | JP7046828B2 (enExample) |
| KR (2) | KR102920104B1 (enExample) |
| AU (2) | AU2017248731B2 (enExample) |
| CA (1) | CA3019426A1 (enExample) |
| IL (2) | IL262207B2 (enExample) |
| MA (1) | MA44873A (enExample) |
| SG (2) | SG11201808426XA (enExample) |
| WO (1) | WO2017180936A1 (enExample) |
Families Citing this family (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015200905A2 (en) | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| IL290457B2 (en) | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| IL262207B2 (en) * | 2016-04-15 | 2026-01-01 | Univ Pennsylvania | Preparations for the treatment of wet age-related macular degeneration |
| CA3076905A1 (en) * | 2017-09-27 | 2019-04-04 | The Johns Hopkins University | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
| MX2020003945A (es) * | 2017-10-18 | 2020-11-09 | Regenxbio Inc | Tratamiento de enfermedades oculares y cancer de colon metastasico con vegf-trap humano modificado post-traduccionalmente . |
| US11766489B2 (en) * | 2017-11-27 | 2023-09-26 | 4D Molecular Therapeutics, Inc. | Adeno-associated virus variant capsids and use for inhibiting angiogenesis |
| CA3086045A1 (en) | 2017-12-19 | 2019-06-27 | Akouos, Inc. | Aav-mediated delivery of therapeutic antibodies to the inner ear |
| US12558434B2 (en) * | 2018-02-20 | 2026-02-24 | The Trustees Of The University Of Pennsylvania | Compositions for treatment of wet age-related macular degeneration |
| CA3092588A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| WO2020019002A1 (en) * | 2018-07-20 | 2020-01-23 | University Of Utah Research Foundation | Gene therapy for macular degeneration |
| JP2022049718A (ja) * | 2019-02-05 | 2022-03-30 | アステラス製薬株式会社 | アデノ随伴ウイルスを用いたｃｘ３ｃｌ１遺伝子の導入による網膜変性疾患の治療 |
| EP4667578A3 (en) * | 2019-04-03 | 2026-04-01 | REGENXBIO Inc. | Gene therapy for eye pathologies |
| US20220195462A1 (en) * | 2019-04-24 | 2022-06-23 | Regenxbio Inc. | Fully-human post-translationally modified antibody therapeutics |
| WO2020243659A1 (en) * | 2019-05-31 | 2020-12-03 | University Of Florida Research Foundation, Incorporated | Vector-based therapy for thyroid disease |
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| CA3149401A1 (en) | 2019-08-26 | 2021-03-04 | Stephen Joseph Pakola | Treatment of diabetic retinopathy with fully-human post-translationally modified anti-vegf fab |
| WO2021071835A1 (en) * | 2019-10-07 | 2021-04-15 | Regenxbio Inc. | Adeno-associated virus vector pharmaceutical composition and methods |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| WO2021231491A1 (en) * | 2020-05-11 | 2021-11-18 | University Of Florida Research Foundation, Incorporated | Disease correction by delivery of aav8 vectors expressing codon optimized naglu |
| AU2021271635A1 (en) * | 2020-05-12 | 2023-01-05 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of krabbe disease |
| WO2021255589A1 (en) * | 2020-06-16 | 2021-12-23 | Intas Pharmaceuticals Ltd. | An anti-vegf scfab adeno-associated virus (aav) vector and uses thereof |
| WO2021255590A1 (en) * | 2020-06-16 | 2021-12-23 | Intas Pharmaceuticals Ltd. | An anti-vegf scfv adeno-associated virus (aav) vector and uses thereof |
| CN113952473A (zh) * | 2020-07-21 | 2022-01-21 | 英斯培瑞有限公司 | 用于治疗眼部疾病的组合物和方法 |
| KR20230088630A (ko) * | 2020-10-16 | 2023-06-20 | 자이로스코프 테라퓨틱스 리미티드 | 항-vegf 엔티티 및 음성 보체 조절인자를 코딩하는 핵산 및 연령-관련 황반 변성의 치료를 위한 그의 용도 |
| AU2021371307A1 (en) * | 2020-10-28 | 2023-06-01 | Regenxbio, Inc. | VECTORIZED ANTI-TNF-α ANTIBODIES FOR OCULAR INDICATIONS |
| KR20230098176A (ko) * | 2020-10-29 | 2023-07-03 | 리젠엑스바이오 인크. | 안구 적응증을 위한 벡터화된 tnf-알파 길항제 |
| IL303317A (en) * | 2020-12-01 | 2023-07-01 | Akouos Inc | ANTI-NATURAL ANTIBODY STRUCTURES AND RELATED METHODS FOR THE TREATMENT OF SYMPTOMS ASSOCIATED WITH VESTIBULAR SWANNOMA |
| MX2023008826A (es) | 2021-02-01 | 2023-09-15 | Regenxbio Inc | Terapia génica para lipofuscinosis neuronal ceroidea. |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| AR128422A1 (es) * | 2022-02-02 | 2024-05-08 | Akouos Inc | Construcciones de anticuerpos anti-vegf y métodos relacionados para el tratamiento de los síntomas asociados al schwannoma vestibular |
| AU2023250660A1 (en) | 2022-04-06 | 2024-10-24 | Regenxbio Inc. | Pharmaceutical composition comprising a recombinant adenoassociated virus vector with an expression cassette encoding a transgene for suprachoroidal administration |
| EP4593955A1 (en) | 2022-09-30 | 2025-08-06 | RegenxBio Inc. | Treatment of ocular diseases with recombinant viral vectors encoding anti-vegf fab |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
| WO2025073297A1 (zh) * | 2023-10-06 | 2025-04-10 | 甘李药业股份有限公司 | 表达抗vegf融合蛋白的aav病毒载体及其用途 |
| WO2025160405A1 (en) * | 2024-01-24 | 2025-07-31 | Duke University | Compositions and methods for generation and secretion of aav particles |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUT73101A (en) | 1993-02-12 | 1996-06-28 | Harvard College | Method for regulating transcription of targeted genes and other biological events |
| ATE544776T1 (de) | 1994-12-29 | 2012-02-15 | Massachusetts Inst Technology | Chimäre dna-bindeproteine |
| KR19990022651A (ko) | 1995-06-07 | 1999-03-25 | 데이비드 엘. 버스테인 | 생물학적 사건에 대한 라파마이신 기재 조절방법 |
| US6884879B1 (en) | 1997-04-07 | 2005-04-26 | Genentech, Inc. | Anti-VEGF antibodies |
| JP2003524368A (ja) | 1997-08-26 | 2003-08-19 | アリアド ジーン セラピューティクス インコーポレイテッド | ニ量化ドメイン、三量化ドメインまたは四量化ドメインおよび補足的非相同転写活性化ドメイン、転写抑制ドメイン、ｄｎａ結合ドメインまたはリガンド結合ドメインを含む融合蛋白 |
| IL134643A0 (en) | 1997-08-27 | 2001-04-30 | Ariad Gene Therapeutics Inc | Chimeric transcriptional activators and compositions and uses related thereto |
| WO1999036553A2 (en) | 1998-01-15 | 1999-07-22 | Ariad Gene Therapeutics, Inc. | Regulation of biological events using multimeric chimeric proteins |
| JP2002503667A (ja) | 1998-02-13 | 2002-02-05 | プレジデント・アンド・フェローズ・オブ・ハーバード・カレッジ | 新規な二量体化剤、その製造および使用 |
| US6596535B1 (en) | 1999-08-09 | 2003-07-22 | Targeted Genetics Corporation | Metabolically activated recombinant viral vectors and methods for the preparation and use |
| US7067526B1 (en) | 1999-08-24 | 2006-06-27 | Ariad Gene Therapeutics, Inc. | 28-epirapalogs |
| CA2388432A1 (en) | 1999-10-21 | 2001-04-26 | Monsanto Company | Post-translational modification of recombinant proteins produced in plants |
| GB2362884A (en) | 2000-05-30 | 2001-12-05 | Isis Innovation | Extended duration of airway gene therapy |
| US20020068694A1 (en) | 2000-07-26 | 2002-06-06 | Jeltsch Markku Michael | Glycosylated VEGF-B and method for increasing the amount of soluble VEGF-B |
| CN103589692B (zh) | 2001-11-13 | 2018-07-24 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
| DK2359869T3 (en) | 2001-12-17 | 2019-04-15 | Univ Pennsylvania | Sequences of adeno-associated virus (AAV) serotype 8, vectors containing these, and uses thereof |
| MXPA04007583A (es) | 2002-02-11 | 2005-04-25 | Genentech Inc | Variantes de anticuerpo con tasas mas rapidas de asociacion a antigeno. |
| US20040208847A1 (en) | 2003-03-28 | 2004-10-21 | Fabienne Rolling | Method and vectors for selectively transducing retinal pigment epithelium cells |
| EP1668143B1 (en) | 2003-09-30 | 2013-03-20 | The Trustees of The University of Pennsylvania | Adeno-associated virus (aav) clades, sequences, vectors containing same, and uses therefor |
| DE23193606T1 (de) | 2005-04-07 | 2024-02-15 | The Trustees Of The University Of Pennsylvania | Verfahren zur erhöhung der funktion eines aav-vektors |
| JP4495210B2 (ja) | 2005-06-09 | 2010-06-30 | パナソニック株式会社 | 振幅誤差補償装置及び直交度誤差補償装置 |
| HUE024877T2 (en) | 2007-10-30 | 2016-02-29 | Genentech Inc | Antibody purification by cation exchange chromatography |
| TWI468417B (zh) | 2007-11-30 | 2015-01-11 | Genentech Inc | 抗－ｖｅｇｆ抗體 |
| KR101010352B1 (ko) | 2008-05-30 | 2011-01-25 | 삼성중공업 주식회사 | 전력 제어 장치 및 방법 |
| US9221902B2 (en) | 2008-11-07 | 2015-12-29 | Fabrus, Inc. | Combinatorial antibody libraries and uses thereof |
| US8734809B2 (en) * | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| RU2567639C2 (ru) | 2009-06-17 | 2015-11-10 | АббВай Биотерапеутикс Инк., | Антитела против vegf и их применения |
| US8927514B2 (en) | 2010-04-30 | 2015-01-06 | City Of Hope | Recombinant adeno-associated vectors for targeted treatment |
| US8628966B2 (en) | 2010-04-30 | 2014-01-14 | City Of Hope | CD34-derived recombinant adeno-associated vectors for stem cell transduction and systemic therapeutic gene transfer |
| US8663624B2 (en) * | 2010-10-06 | 2014-03-04 | The Regents Of The University Of California | Adeno-associated virus virions with variant capsid and methods of use thereof |
| US10738326B2 (en) | 2010-10-27 | 2020-08-11 | Jichi Medical University | Adeno-associated virus vector for gene transfer to nervous system cells |
| CA2826273C (en) | 2011-02-10 | 2021-11-02 | The University Of North Carolina At Chapel Hill | Viral vectors with modified transduction profiles and methods of making and using the same |
| JP6091435B2 (ja) * | 2011-02-22 | 2017-03-08 | カリフォルニア インスティチュート オブ テクノロジー | アデノ随伴ウイルス（ａａｖ）ベクターを用いたタンパク質の送達 |
| DK3693025T3 (da) | 2011-04-22 | 2022-01-10 | Univ California | Adenoassocierede virus-virioner med variant capsid og fremgangsmåder til anvendelse heraf |
| EP2559443A1 (en) | 2011-08-16 | 2013-02-20 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of an ocular disease in a subject |
| EP3795581A3 (en) | 2011-08-24 | 2021-06-09 | The Board of Trustees of the Leland Stanford Junior University | New avv capsid proteins for nucleic acid transfer |
| US20130090375A1 (en) | 2011-10-06 | 2013-04-11 | Cornell University | Virus-mediated delivery of bevacizumab for therapeutic applications |
| EP3470523A1 (en) | 2012-05-09 | 2019-04-17 | Oregon Health & Science University | Adeno associated virus plasmids and vectors |
| TWI698240B (zh) | 2012-05-15 | 2020-07-11 | 澳大利亞商艾佛蘭屈澳洲私營有限公司 | 使用腺相關病毒(aav)sflt-1治療老年性黃斑部退化(amd) |
| AU2013342275B2 (en) | 2012-11-08 | 2017-11-09 | Clearside Biomedical, Inc. | Methods and devices for the treatment of ocular diseases in human subjects |
| US20140154255A1 (en) * | 2012-11-30 | 2014-06-05 | Abbvie Biotherapeutics Inc. | Anti-vegf antibodies and their uses |
| WO2014124282A1 (en) | 2013-02-08 | 2014-08-14 | The Trustees Of The University Of Pennsylvania | Enhanced aav-mediated gene transfer for retinal therapies |
| EP2970946A4 (en) | 2013-03-13 | 2016-09-07 | Philadelphia Children Hospital | ADENOASSOZED VIRUS VECTORS AND METHOD FOR USE THEREOF |
| BR112015021036A2 (pt) | 2013-03-15 | 2017-10-10 | Univ Pennsylvania | composições e métodos para tratar mps1 |
| EP3564379A1 (en) | 2013-09-13 | 2019-11-06 | California Institute of Technology | Selective recovery |
| HUE052676T2 (hu) | 2013-10-11 | 2021-05-28 | Massachusetts Eye & Ear Infirmary | Eljárások õsi vírusszekvenciák elõrejelzésére és alkalmazásaik |
| RS61993B1 (sr) | 2013-12-03 | 2021-07-30 | Hookipa Biotech Gmbh | Cmv vakcine |
| GB201403684D0 (en) | 2014-03-03 | 2014-04-16 | King S College London | Vector |
| US11555059B2 (en) | 2014-04-25 | 2023-01-17 | The Trustees Of The University Of Pennsylvania | LDLR variants and their use in compositions for reducing cholesterol levels |
| US10746742B2 (en) | 2014-04-25 | 2020-08-18 | Oregon Health & Science University | Methods of viral neutralizing antibody epitope mapping |
| CR20160519A (es) | 2014-05-13 | 2017-01-27 | The Trustees Of The Univ Of Pennysylvania | Composiciones que comprenden avv que expresa constructos de anticuerpos duales y sus usos |
| US10577627B2 (en) | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| WO2015200905A2 (en) * | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| US10064752B2 (en) | 2014-09-11 | 2018-09-04 | Orbit Biomedical Limited | Motorized suprachoroidal injection of therapeutic agent |
| CA2977355A1 (en) | 2015-02-20 | 2016-08-25 | University Of Iowa Research Foundation | Methods and compositions for treating genetic eye diseases |
| WO2016200543A2 (en) * | 2015-05-13 | 2016-12-15 | The Trustees Of The University Of Pennsylvania | Aav-mediated expression of anti-inluenza antibodies and methods of use thereof |
| EP3344294A4 (en) | 2015-08-31 | 2019-03-20 | The Trustees Of The University Of Pennsylvania | CHIMERIC AAV ANTI-VEGF FOR THE TREATMENT OF CANCER IN DOGS |
| GB201519086D0 (en) | 2015-10-28 | 2015-12-09 | Syncona Partners Llp | Gene Therapy |
| CN108778330A (zh) | 2016-01-08 | 2018-11-09 | 科尼尔赛德生物医学公司 | 用阿柏西普和其他生物制品治疗后眼部障碍的方法和装置 |
| IL262207B2 (en) * | 2016-04-15 | 2026-01-01 | Univ Pennsylvania | Preparations for the treatment of wet age-related macular degeneration |
| JP2019515027A (ja) | 2016-04-15 | 2019-06-06 | レジェンクスバイオ インコーポレーテッド | 翻訳後修飾された完全ヒト抗ＶＥＧＦ Ｆａｂを用いる眼疾患の治療 |
| CA3076905A1 (en) | 2017-09-27 | 2019-04-04 | The Johns Hopkins University | Treatment of ocular diseases with fully-human post-translationally modified anti-vegf fab |
| EP4667578A3 (en) | 2019-04-03 | 2026-04-01 | REGENXBIO Inc. | Gene therapy for eye pathologies |
-
2017
- 2017-04-14 IL IL262207A patent/IL262207B2/en unknown
- 2017-04-14 AU AU2017248731A patent/AU2017248731B2/en active Active
- 2017-04-14 KR KR1020237029712A patent/KR102920104B1/ko active Active
- 2017-04-14 KR KR1020187032620A patent/KR102574810B1/ko active Active
- 2017-04-14 SG SG11201808426XA patent/SG11201808426XA/en unknown
- 2017-04-14 MA MA044873A patent/MA44873A/fr unknown
- 2017-04-14 EP EP17734161.7A patent/EP3452103A1/en active Pending
- 2017-04-14 WO PCT/US2017/027529 patent/WO2017180936A1/en not_active Ceased
- 2017-04-14 CA CA3019426A patent/CA3019426A1/en active Pending
- 2017-04-14 IL IL322403A patent/IL322403A/en unknown
- 2017-04-14 US US16/093,420 patent/US11197937B2/en active Active
- 2017-04-14 JP JP2018554334A patent/JP7046828B2/ja active Active
- 2017-04-15 SG SG10201913159UA patent/SG10201913159UA/en unknown
-
2021
- 2021-06-07 US US17/340,752 patent/US20220288238A1/en not_active Abandoned
-
2022
- 2022-03-23 JP JP2022046261A patent/JP7111924B2/ja active Active
- 2022-07-21 JP JP2022116098A patent/JP7492556B2/ja active Active
-
2024
- 2024-05-17 JP JP2024080598A patent/JP2024105617A/ja active Pending
- 2024-08-23 AU AU2024216307A patent/AU2024216307A1/en active Pending
-
2025
- 2025-12-17 US US19/423,915 patent/US20260224753A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021516671A5 (enExample) | ||
| JP2024016207A5 (enExample) | ||
| FI3717636T3 (fi) | Adenoassosioidun viruksen kapsidivariantteja ja käyttö angiogeneesin estämisessä | |
| JP2020114218A5 (enExample) | ||
| JP2020028308A5 (enExample) | ||
| JP2020528734A5 (enExample) | ||
| RU2016135771A (ru) | Композиции и способы лечения и предотвращения дегенерации желтого пятна | |
| CN110650733A (zh) | 经过修饰的aav衣壳和其用途 | |
| FI4206216T3 (fi) | Adenoassosioituneen viruksen kapsidimuunnoksia ja menetelmiä niiden käyttämiseksi | |
| JP2017506230A5 (enExample) | ||
| JP2018508519A5 (enExample) | ||
| JP2020510424A5 (enExample) | ||
| JP7685070B2 (ja) | 血管新生に関連する眼疾患の処置のための組成物および方法 | |
| JP2015523060A5 (enExample) | ||
| JP2018527941A5 (enExample) | ||
| JP2024105617A (ja) | 滲出型加齢性黄斑変性の治療のための組成物 | |
| CA2995849A1 (en) | Chimeric aav-anti-vegf for treating cancer in canines | |
| JP7845822B2 (ja) | 発現ベクター及び方法 | |
| US20190240328A1 (en) | Novel humanized anti-ebola antibodies useful in preventing ebola infections | |
| CN119585299A (zh) | 编码抗vegf实体和补体负调节剂的核酸及其用于年龄相关性黄斑变性的治疗的用途 | |
| WO2025034741A1 (en) | Compositions and methods for expressing therapeutics | |
| US20250074974A1 (en) | Angiogenesis inhibitor-conjugated anti-c3b antibody or anti-c5 antibody and use thereof | |
| CN117736274A (zh) | 一种腺相关病毒衣壳蛋白及其用途 | |
| WO2025133635A1 (en) | Therapies for preventing or treating inflammatory eye disease | |
| NZ765038B2 (en) | Adeno-associated virus variant capsids and use for inhibiting angiogenesis |